Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Receivables - Other: 2016-2025

Historic Receivables - Other for Akebia Therapeutics (AKBA) over the last 8 years, with Sep 2025 value amounting to $3.1 million.

  • Akebia Therapeutics' Receivables - Other rose 67.67% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 67.67%. This contributed to the annual value of $2.0 million for FY2024, which is 39.69% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Receivables - Other of $3.1 million as of Q3 2025, which was down 43.00% from $5.4 million recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Receivables - Other high stood at $56.6 million for Q2 2022, and its period low was $417,000 during Q1 2023.
  • For the 3-year period, Akebia Therapeutics' Receivables - Other averaged around $2.1 million, with its median value being $1.8 million (2024).
  • In the last 5 years, Akebia Therapeutics' Receivables - Other surged by 1,910.15% in 2022 and then crashed by 99.07% in 2023.
  • Quarterly analysis of 5 years shows Akebia Therapeutics' Receivables - Other stood at $19.1 million in 2021, then crashed by 90.04% to $1.9 million in 2022, then spiked by 75.33% to $3.3 million in 2023, then slumped by 39.69% to $2.0 million in 2024, then skyrocketed by 67.67% to $3.1 million in 2025.
  • Its Receivables - Other was $3.1 million in Q3 2025, compared to $5.4 million in Q2 2025 and $1.6 million in Q1 2025.